PLANO, Texas–(BUSINESS WIRE)– #CardiovascularResearch–Secretome Therapeutics, a clinical-stage biotechnology company developing novel therapies derived from neonatal cardiac progenitor cells (nCPC), today announced that clinical data from its Phase 1 study evaluating STM-01 in patients with heart failure with preserved ejection fraction (HFpEF) will be presented at the Heart Failure Society of America (HFSA) Annual Scientific Meeting.STM-01 is an investigational biologic therapy derived from neonatal cardiac progenito

Subscribe to Our Newsletter

We keep your data private and share your data only with third parties that make this service possible. See our Privacy Policy for more information.